personalised medicine
How to Create a Competitive Advantage with Big Data Analytics in Pharma
April 24 by Pharmaceuticals & Biotechnology EditorIn the build up to the Big Data Analytics in Pharma Summit, Andrea Charles, Editor at Pharma IQ spoke to Nigel Hughes, Director Integrative Healthcare Informatics, Janssen R&D, to take closer lo...
Are we in Danger of Suffering from a Data & Information Overload in Healthcare IT?
June 11 by Andrea CharlesHealthcare informatics is a discipline that is ever-changing from mobile devices, to cloud-based computing to language technology, with the rise in genomics and preventative medicine we ca...
Pharma IQ's Top Ten Pharmaceutical Associations
May 23 by Pharma IQAt Pharma IQ we work with lots of pharmaceutical associations and we wanted to put a list together of our favourite top ten! With that in mind we are pleased to be able to release the first in our ser...
Personalized Medicine –A Game with More Than One Nash Equilibrium
January 12 by Cristina FalcãoThere is a time and the time is now and is right for me… (1) Welcome to the age of personalized medicine. With the mapping of the entire human genome, completed in 2003, many doors were un...
Orphan Drugs are Forerunners of Personalised Medicine
October 20 by Cristina FalcãoMarketing exclusivity in EU and U.S.A provided a monopolistic market for orphan drugs without “me-too”/generics competitors, to pharma companies. Orphan drug laws and the pharma indus...
Why Not Sequence the Whole Genome?
September 13 by Andrea CharlesProfessor René Bernards, Head of the Division/Group Leader, Molecular Carcinogenesis at The Netherlands Cancer Institute, joins Andrea Charles from Pharma IQ, to discuss current trends in next-ge...
The Road To ‘Personalised Medicine’ with AstraZeneca's Duncan McHale
August 17 by Pharmaceuticals & Biotechnology EditorDuncan McHale, Vice-President for Personalised Healthcare and Biomarkers, Astrazeneca, joins Helen Winsor of Pharma IQ. In this interview he discusses the importance of biomarker discov...
Achieving the 4 Rights in Effective Health Care: An Interview with Peter Pitts
January 07 by Andrea CharlesAs part of the new Pharma Leaders Today series, Peter Pitts, President and co-founder of the Center for Medicine in the Public Interest and Partner/Director Global Healthcare, Porter Novelli,&nbs...
Personalised Medicine: Is Co-Development the Best Method for Companion Diagnostics?
December 10 by Pharma IQThe market potential for personalised medicines is growing, thanks to the opportunities they hold for both patients and drug developers. Research conducted by Tufts Center for the Study of D...
Market for CNS Biomarkers Predicted to Grow to $3.2 Billion by 2015
December 02 by Pharma IQBiomarkers are now being used by a large number of companies in the biopharmaceutical industry - and one of the key therapeutic areas where they are utilised is in CNS drug development, wher...
Is Co-development the Best Method for Companion Diagnostics?
April 25 by Paul de KoningPaul de Koning, Vice President, Head Global Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, joins Pharma IQ to discuss targeted treatment and diagnostics....